United Health Products, Inc. (OTCQB: UEEC) has provided an update on its regulatory progress with the Food & Drug Administration (FDA) regarding its Investigational Device Exemption (IDE) application. The company's application for a follow-on clinical study involving 27 patients undergoing organ space procedures was initially reviewed by the FDA's Office of Product Evaluation and Quality, which found no deficiencies. However, the company must first address findings from a Bioresearch Monitoring (BIMO) audit of its 2019 clinical study before proceeding.
The FDA's Division of Clinical Policy and Quality issued the BIMO audit assessment on March 24, 2025, to which United Health Products submitted a detailed response on April 14. The FDA's review of this response is currently ongoing. The outcome of this review is pivotal for the company, as it determines the timeline for patient enrollment in the clinical study of its CelluSTAT Hemostatic Gauze, a product designed to control mild to moderate bleeding in surgical settings.
United Health Products has completed all preparatory tasks for the study, pending IDE approval. The CelluSTAT Hemostatic Gauze represents a potential advancement in surgical bleeding control, offering an all-natural solution. The FDA's decision on the BIMO audit findings is therefore not only crucial for the company but also for the broader medical community and patients who could benefit from this innovative product.
